BactiQuant AS (FRA:9JX) EBIT: €-1.66 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9JX BactiQuant AS FRA:9JX
56 GF Score
Price €0.29
GF Value €0.27
! 4 Warning Signs
View Full Analysis

What is BactiQuant AS EBIT?

BactiQuant AS FRA:9JX +2.15% 56 EBIT is €-1.66 Mil as of Dec. 2025. GuruFocus rates FRA:9JX with a GF Score™ of 56/100 and a GF Value™ of €0.27. The stock has 4 warning signs investors should review.

BactiQuant AS's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-0.81 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.66 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BactiQuant AS's annualized ROC % for the quarter that ended in Dec. 2025 was -132.95%. BactiQuant AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -334.57%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BactiQuant AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -15.73%.

BactiQuant AS  (FRA:9JX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BactiQuant AS's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-1.636 * ( 1 - 0% )/( (1.336 + 1.125)/ 2 )
=-1.636/1.2305
=-132.95 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.509 - 0.122 - ( 1.051 - max(0, 0.382 - 1.777+1.051))
=1.336

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.758 - 0.241 - ( 2.392 - max(0, 0.524 - 3.152+2.392))
=1.125

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

BactiQuant AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.626/( ( (0.109 + max(0.441, 0)) + (0.058 + max(0.364, 0)) )/ 2 )
=-1.626/( ( 0.55 + 0.422 )/ 2 )
=-1.626/0.486
=-334.57 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.081 + 0.533 + 0) - (0.122 + 0 + 0.051)
=0.441

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.123 + 0.531 + 0) - (0.241 + 0 + 0.049)
=0.364

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BactiQuant AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-1.661/10.561
=-15.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BactiQuant AS EBIT Related Terms

BactiQuant AS EBIT Historical Data

* Premium members only.

The historical data trend for BactiQuant AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BactiQuant AS EBIT Chart

BactiQuant AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -1.70 -1.83 -1.55 -1.65 -1.66

BactiQuant AS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.81 -0.94 -0.71 -0.85 -0.81

FRA:9JX vs VLTO, ZWS, CECO: EBIT Comparison

For the Pollution & Treatment Controls subindustry, BactiQuant AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BactiQuant AS EV-to-EBIT vs Industrial Products Industry

For the Industrial Products industry and Industrials sector, BactiQuant AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BactiQuant AS's EV-to-EBIT falls into.


FRA:9JX
56GF Score
BactiQuant AS FRA:9JX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BactiQuant AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-1.66 Mil mean?
BactiQuant AS (FRA:9JX) has a EBIT of €-1.66 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BactiQuant AS.
Is BactiQuant AS's EBIT too high?
BactiQuant AS's current EBIT is €-1.66 Mil. Overall, BactiQuant AS has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does BactiQuant AS's EBIT compare to VLTO and ZWS?
BactiQuant AS's EBIT of €-1.66 Mil can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for an Industrial Products company?
A good EBIT depends on the Industrial Products industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BactiQuant AS. BactiQuant AS's current EBIT is €-1.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BactiQuant AS stock overvalued right now?
BactiQuant AS (FRA:9JX) has a current EBIT of €-1.66 Mil. The stock's GF Value™ is €0.27, compared to a current price of €0.29 — trading 5.6% above its estimated fair value. The current EBIT is €-1.66 Mil. BactiQuant AS's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For BactiQuant AS (FRA:9JX), the current EBIT is €-1.66 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BactiQuant AS (FRA:9JX) Overvalued in 2026?

Based on GuruFocus' analysis, BactiQuant AS stock appears to be overvalued. The current stock price of €0.29 is trading 5.6% above its estimated GF Value™ of €0.27.

Key valuation signals for FRA:9JX:

  • EBIT: €-1.66 Mil
  • GF Value™: €0.27 vs. price of €0.29 (5.6% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the FRA:9JX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BactiQuant AS Business Description

Other Exchanges BACTIQ:Denmark
Address Blokken 75, Birkeroed, DNK, DK-3460
BactiQuant AS focuses on delivering technology that ensures optimum usage and handling of water around the world. The company's activities include the development, production, sale and service of BactiQuant Online and BactiQuant Mobile Lab with associated test kits/substrate for the quantification and detection of bacteria in water. Its segments are Aquaculture, Data Centres, Oil & Gas, Water Utility, Industry, and Pharma. The group's products are BQ Online 2.0 PRO, BQ Online, BQ Mobile Lab, and Analysis Kits.
56GF Score

Get the complete analysis for FRA:9JX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.29
Price
€0.27
GF Value